Export

ATC codes: J01XX08
EMLc
Indication
Multi-drug resistant Mycobacterium tuberculosis ICD11 code: ML32.00
INN
Linezolid
Medicine type
Chemical agent
Antibiotic groups
List type
Complementary (EML)
(EMLc)
Additional notes
Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB contol.
Formulations
Oral > Solid: 600 mg tablet ; 150 mg tablet (dispersible) (EMLc)
EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Committee recommended deletion from the EML and/or EMLc of various formulations and strengths of amikacin (injection: 100 mg/2 mL (as sulfate) in 2 mL vial), ethambutol (Oral liquid: 25 mg/mL), ethionamide (tablet: 125 mg), isoniazid (oral liquid: 50 mg/5 mL), linezolid (powder for oral liquid: 100 mg/5 mL), p-aminosalicylic acid (granules: 4 g in sachet) and pyrazinamide (oral liquid: 30 mg/mL), noting that they are not optimal formulations and strengths for tuberculosis treatment.